Abstract Purpose: A33 antigen is a membrane-bound protein expressed in intestinal epithelium that is overexpressed in 95% of primary and metastatic colorectal carcinomas but is absent in most epithelial tissues and tumor types. We hypothesized that A33 promoter might be useful in the design of a conditionally replicative adenovirus for the treatment of colorectal cancer (CRC). (1) . The liver is the most common site of metastatic CRC and complete resection of hepatic metastases is the only curative option; however, surgery can be done only in 20% of patients
at the time of diagnosis and 5-year survival rates average 25% to 40% despite adjuvant chemotherapy (2) . Among patients with metastatic colorectal carcinoma receiving as first-line chemo therapy 5-fluorouracil (5-FU) and new medications, such as irinotecan, Xeloda, oxaliplatin, Erbitux, and Avastin, the median time to progression is 8 to 9 months and their mean survival is 15 to 20.5 months (3) (4) (5) (6) . It seems therefore that current CRC treatments are rather ineffective on advanced disease, showing the need for more effective and specific therapeutics to significantly increase patients' survival.
Conditionally replicative oncolytic adenoviruses (CRAd) have shown promising applications in cancer gene therapy (7, 8) . One strategy to achieve specific elimination of the tumor mass, avoiding negative undesired effects in contiguous normal tissue, is the use of tumor-selective transcriptional regulation to control the essential early El genes, which are required to transactivate the other adenoviral genes (9, 10) . Several promoters have been used to drive adenoviral replication and oncolytic activity in colorectal carcinoma, including the carcinoembryonic antigen (CEA), the telomerase, and the cyclooxygenase-2 (COX-2) promoters, which might provide a broad spectrum of therapeutic efficacy. Despite the strong oncolytic efficacy of these viruses, there is still a concern about their stringent selectivity. CEA and COX-2 promoters were
Translational Relevance
We provide here preclinical data about the therapeutic efficacy of a novel oncolytic adenoviral vector, AV22EL, for treatment of colorectal cancer (CRC). AV22EL replica tion was driven by a CRC-specific A33 antigen promoter. A33 is a membrane-bound protein located in the intestinal epithelium that is overexpressed in 95% of primary and metastatic CRC but is absent in most epithelial tissues and tumor types. A specific anti-A33 antibody is already in clin ical use, suggesting its clinical relevance. AV22EL induced specifically the in vitro lysis of cells of CRC origin while showing almost no lytic activity on other cancer cell lines. AV22EL exhibited no cytocidal effect on normal human colonic cells and hepatocytes, whereas these cells were eliminated by wild-type adenovirus. AV22EL markedly reduced the in vivo growth in nude mice of established CRC and showed an additive effect in vitro when combined with 5-fluorouracil with no evidence of further toxic effects in vivo. Its systemic administration induced the disappear ance of hepatic metastatic nodules in >90% of mice and restored normal levels of hepatic enzymes following metas tases disappearance, exhibiting no evidence of viral activity in normal organs, including normal intestine, as assessed by E1A and luciferase expression. Thus, AV22EL fulfills the criteria to become a useful and strongly specific tool for treatment of patients with CRC.
shown to be active in CEA-negative and COX-2 -negative cells, respectively (11) (12) (13) , the telomerase promoter could be active in CD34+ and other progenitors cells (14) , whereas the use of an oncolytic virus based on the COX-2 promoter could be hampered by the rise of COX-2 expression in transient or chronic inflammation (15) . An oncolytic virus was also designed based on a wnt-responding element because this pathway is strongly up-regulated in CRC; however, the wnt pathway is also active in normal stem cells in skin, the hematopoietic system, and in intestine, as well as in neurons in several brain regions (16) , although adenovirus hardly infects kératinocytes and hematopoietic cells, diminishing the risks for undesirable collateral effects (17, 18) . However, the possibility of generating an oncolytic virus based on stringent, cancer type-specific promoter might have the advantage of its strong attenuation in normal organs, increasing the effectiveness for systemic treatment of disseminated disease.
The A3 3 antigen is a cell surface glycoprotein present only in the small intestine and colonic epithelium with homology to proteins of the immunoglobulin superfamily, such as the coxsackievirus and adenovirus receptor (19) . In human cancer, A33 was found in 95% of primary and metastatic colorectal carcinomas, 63% of diffuse gastric cancers, 83% of intestinaltype gastric cancers, 50% of pancreatic cancers, and ~ 50% of the diffuse-type and mucinous cancers; it was absent in epithelial cancers, sarcomas, neuroectodermal tumors, and lymphoid neoplasms (20, 21) . A3 3 is the first example of a constitutively expressed, organ-specific epithelial membrane antigen present in patients with gastrointestinal cancer (20) . A3 3 seems to be expressed by normal replicating colonocytes located at the base of the crypt that in principle should not be accessible to an oncolytic virus (20) . This restricted tissue localization and specific expression of A3 3 in gastrointestinal cancer led to the initiation of clinical trials in CRC aiming to target A33 by using specific antibody immunotherapy (22) (23) (24) (25) (26) .
Initial data obtained from clinical studies using oncolytic viruses have been encouraging in terms of efficacy with minimal, if any, toxicity (27) 
Materials and Methods

Cell lines
The human CRC ( 
Assessment of A33 mRNA expression
Total RNA was extracted using Tri Reagent (Sigma-Aldrich Co.). RNA (5 
Construction of AV22EL and other recombinant adenoviruses
A 412-bp fragment of the human A33 promoter region (-105 to +307 bp relative to the transcription start site) was amplified from human lymphocyte genomic DNA using specific primers (Supplementary Table SI ). The PCR product was cloned in pGEM-T easy vector (Promega Corp.) followed by subcloning in the Bg/II/X/ioI sites of the promoterless firefly luciferase gene reporter vector pGL3-Basic (Promega) to obtain pGL3-A33.
We replaced the Rous sarcoma virus promoter of the shuttle vector pADPSY (28) 
Assessment of E1A levels
For determination of E1A mRNA levels, 1.5 x 105 cells per well were seeded in a six-well plate. The next day, cells were infected with the indicated viruses at 1,000 MOI or mock infected. After 24, 48 , and 72 h, cells were lysed and total RNA was obtained. A semiquantitative PCR for E1A was done using the set of primers described in Supplementary Table SI.
Western blot
L0V0 cells were transduced with AV22EL or Ad-WT (kindly provided by Dr. Andre Lieber, Seatde, WA) at various MOIs. After 72 h, total protein extracts were prepared in lysis buffer [10 mmol/L Tris (pH 7.5), 1 mmol/L EDTA, 150 mmol/L NaCl, 1% Triton X-100 (Sigma), 0.5% deoxycholic acid (Sigma), 0.1% SDS with a protease inhibitor cocktail]. Total protein extracts were separated in 10% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad Laboratories). The membranes were probed with anti-ElA antibody (M73; Santa Cruz Biotech) and anti-p-actin antibody (A4700; Sigma) was used as a loading control. Enhanced chemiluminescence reagents were used to detect the signals following the manufacturer's instructions (Amersham).
Cytopathic effect
Cells were seeded in 24-well plates at a density of 1 
Hepatocyte isolation
Liver samples were collected from one patient undergoing partial hepatectomy. Sample collection was obtained under informed consent with the approval of the ethics committee of the Hospital University Austral. Hepatocyte isolation was done under sterile conditions using a modified two-step collagenase perfusion technique (33) . Liver samples were homogenized with 0.1% collagenase for 30 min, twice. Cell suspension was centrifuged at 50 X g for 5 min at 4°C. The cells were purified by density gradient centrifugation (1,278 x g, 20 min, 4°C) using a 25% Percoll solution (density of 1.124 g/mL) in cold PBS. After isolation, hepatic cells were counted and viability was assessed by trypan blue exclusion test. Cells were seeded in collagen type I. At day 5, glycogen storage was detected by procedure periodic acid-Schiff.
In vitro assays combining AV22EL with 5-FU
Cells seeded in 96-well plates (2 X 103 per well) were infected the next day with AV22EL or treated with 5-FU (Microsules Bernabo). In one experimental condition, cells were first treated with 5-FU for 24 h, the medium was then removed, and the cells were transduced with AV22EL. In another experimental condition, cells were first infected with AV22EL for 24 h and then the medium was replaced with fresh medium containing 5-FU. Five days after treatment, cell viability was established with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the absorbance was read at 570 nm using a Bio-Rad Model 550 microplate reader (Bio-Rad Laboratories). All assays were carried out in six different replicates.
Multicellular spheroids
The semisolid liquid overlay culture technique was used to produce multicellular spheroid cultures (34) . Briefly, 1 x 104 cells were seeded onto a semisolid 1% (w/v) agarose per well layer in 96-well plates in 200 |1L of medium. Seventy-two-hour-old spheroids were infected at MOIs of 10, 100, and 500 for 7 d with the different adenoviruses. At the end of the experiment, spheroids were photographed and growth was quantified by regular measurement of cross-sectional area of individual spheroids.
Virus yield
Six-well plates were seeded with 1 X 105 cells per well 24 h before infection. Cells were infected at a MOI of 50 for 2 h in serum-free www.aacrjournals.orgmedium. Then, the virus-containing media were removed, monolayers were washed twice with PBS, and 1 mL of complete medium was added to each well. At 72 h after infection, the cells were scraped into culture medium and lysed by three cycles of freezing and thawing. The supernatant was tested for the viral titer by an end point cytocidal assay as described by Li et al. (35) . For in vivo detection of viral replication, hepatic metastases were fixed in 4% paraformaldehyde for 1 h, cryopreserved overnight in 30% sucrose, embedded in tissue OCT, and stored at -20°C. Cryostat sections (9 pm) were mounted on gelatin-coated slides and incubated with goat anti-adenoviral hexon protein antibody AB1056 (Chemicon International). Biotinylated secondary antibodies were used in con junction with the Vectastain avidin-biotin complex method kit (Vector Laboratories), and finally, the reaction was visualized by using 3,3'-diaminobenzidine chromogen (Dako). Slides were counterstained with hematoxylin and photographed on an Olympus BX60 microscope. The liver metastasis was sectioned in three pieces, each -0.5 mm in width. Histologic analysis was done on one 5-pm tissue section of each piece. (Fig. 1A) . A33 mRNA was not expressed in additional malignant cells, normal fibroblasts, and endothelial cells (Fig. 1A) . A33Pr, cloned in the promoterless plasmid pGL3 basic, was essentially active only in human CRC cells LoVo, T84, and HT29, whereas human mammary and melanoma cells showed strongly reduced activity (Supplemen tary Fig. S1A ). In coincidence, an adenoviral vector expressing the luciferase gene driven by A33Pr (AV-Luc) was highly active only in CRC cells; among A3 3-nonexpressing cells, AV22EL showed a slight activity in SB2 melanoma cells (Fig. IB and see  below) .
In vivo studies on s.c. tumors and hepatic metastases
Assessment of intratumor viral replication
We next constructed a CRAd (AV22EL) where El A was placed under the control of A33Pr (Supplementary Fig. SIB (Fig. 1C) .
Selective replication and lytic activity of AV22EL in CRC cells. AV22EL showed marked in vitro cytocidal effect against LoVo and T84 human CRC cells expressing the highest A33 mRNA levels ( Fig. 2A and B) . AV22EL was at least 2 orders of magnitude less effective on HT29 human colorectal carcinoma cells that expressed the lowest A3 3 mRNA level among the CRC cells ( Fig. 2A and B) . Interestingly, the presence of the E3 region was slightly detrimental for the in vitro lytic activity of the A33Pr-based CRAd (Supplementary Fig. S2A ). AV22EL was only effective at 1,000 MOI on human Hep-3B hepatoma and SB2 melanoma cells, whereas it had essentially no cytocidal effect on human A375 melanoma cells, T47D breast cancer cells, WI-38 and HFL-1 fibroblasts, and bovine aortic endothe lial cells ( Fig. 2A and B) . Ad-WT was active in CRC cells at a lower MOI than AV22EL ( Fig. 2A and B ; Supplementary  Fig. S2B) ; however, its lytic activity was independent of the A3 3 levels expressed by the different cell types ( Fig. 2A and B) .
AV22EL specificity was further confirmed when T84 CRC cells expressing EGFP were mixed in vitro with WI-38 fibroblasts. Under these conditions, only T84-EGFP cells were lysed by AV22EL, whereas neighbor WI-38 fibroblasts were not affected ( Supplementary Fig. S2C and D) . On the other hand, Fig. 1 . Characterization of A33 promoter activity in different cell types. A A33 mRNA levels in different cell types. A33 mRNA levels were assessed as described in Materials and Methods. All the experiments were done in triplicate, and the data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. Columns, mean; bars, SD. B, activity of the A33 promoter. Cells were transduced with 5 x 106 vp/mL of AV-Luc and Ad-CMV Renilla as described in Materials and Methods. Cell extracts were assayed 2 d later for firefly and Renilla luciferase. Columns, mean of three independent experiments; bars, SD. C, Western blot analysis showing E1A expression in LoVo cells infected with AV22EL.
Ad-WT efficiently lysed both cell types ( Supplementary  Fig. S2D ).
As an alternative way to establish the selectivity of AV22EL, cells were infected with AV22EL or Ad-WT and the viral yield was measured by plaque assay at 72 hours after infection. AV22EL replicated very efficiently in LoVo and T84 colon cancer cells, although at a lower level than Ad-WT (Fig. 2C) . On the other hand, AV22EL replicated inefficiently in A33-nonexpressing melanoma and breast cancer cell lines that produced 105-to 10s-fold less progeny than A33-positive cells. The virus did not replicate at all in normal colon cells, fibroblasts, and endothelial cells (Fig. 2C) . Interestingly, HT29 colon cancer cells that express A33 showed viral yield levels similar to those observed in SB2 melanoma cells that did not express A33 (Fig. 2C) . Despite that, AV22EL showed 10-fold higher lytic capacity on HT29 cells compared with SB2. By using a replication-defective adenovirus expressing the l>-galactosidase gene followed by X-Gal staining, we observed that at the largest MOI of 1,000, only 40% of HT29 cells were transduced compared with -100% of SB2 melanoma cells ( Supplementary Fig. S2E ). On the other hand, HT29 CRC cells infected with 1,000 MOI of AV22EL exhibited clearly detectable levels of E1A, whereas only faint levels of El A were seen in SB2 melanoma cells under the same conditions ( Supplementary  Fig. S2F ). Ad-WT infection led to similar E1A expression levels in both HT29 and SB2 cells ( Supplementary Fig. S2F ). These data show that AV22EL replicates in HT29 cells at a better extent compared with SB2 melanoma cells, although, based on El A expression, it seems that SB2 melanoma cells can support a certain level of AV22EL replication.
Complete attenuation of AV22EL lytic capacity on normal human colonic cells and hepatocytes. To further establish that AV22EL activity was attenuated in normal cells, we assessed its cytocidal effect on CCD841 and FHC cells derived from normal colon epithelia. Ad-WT efficiently lysed both LoVo colorectal carcinoma cells and normal colonic epithelial cells at a MOI of 100 (Fig. 3A) . However, AV22EL exerted a cytocidal effect on LoVo cells but had no lytic effect on CCD841 and FHC cells, suggesting that AV22EL is strongly attenuated in normal colonic cells (Fig. 3A) . Of relevance was also the evidence that AV22EL had no lytic activity on normal human hepatocytes at the largest MOI of 1,000, whereas Ad-WT exhibited a strong lytic effect (Fig. 3B ). The inset also shows that Ad-WT, but not AV22EL, could replicate in normal hepatocytes (Fig. 3B ).
AV22EL lytic capacity on cells growing in multicellular
spheroids. Multicellular spheroids represent a tridimensional in vitro model of an avascular growing tumor. Three-day-old spheroids were infected in situ with AV22EL or Ad-WT at different MOIs and followed for additional 7 days. At the end of the experiment, spheroids were photographed and sized. Zero MOI corresponds to the average volume of noninfected spheroids at the end of the experiment ( Fig. 4 ; Supplementary Table S2 ). Spheroids contained in average 5,000 cells at the beginning of the experiment, whereas noninfected spheroids grew up to an average of 30,000 cells/each after 7 days (Supplementary Fig. S3A ). In the photography, A375N spheroid volume seems larger due to the fact that A375N cell size is larger than the others (data not shown). Ad-WT inhibited -50% the growth of spheroids made of A375N and SB2 melanoma cells, whereas AV22EL had essentially no inhibitory effect ( Fig. 4A; Supplementary Table S2 (Fig. 5A, left) , including complete tumor regression in two mice that lasted for 200 days (data not shown). However, AV22EL did not affect SB2 melanoma cell growth despite an initial inhibitory effect (Fig. 5A, left) that is probably in accordance with the faint El A levels reflecting viral replication that were observed after SB2 infection with AV22EL ( Supplementary Fig. S2F (Fig. 5B, a) . T84 cells were highly sensitive to 5-FU alone (Fig. 5B, a) . When 5-FU concentration was lowered to 0.1 pg/mL, we observed that 10 MOI of AV22EL significantly enhanced the lytic effect of 5-FU on the three colon cancer cell lines compared with 5-FU alone (Fig. 5B, b) . AV22EL was completely attenuated in normal cells because it was unable to enhance the growth inhibition induced by 5-FU on normal colon cells and fibroblasts (Fig. 5B, c) . We next evaluated if this improved inhibitory effect in vitro could be extrapolated in vivo. Mice harboring s.c. LoVo tumors were treated with PBS, 5-FU alone, AV22EL alone, or the combination of AV22EL followed by 5-FU. 5-FU alone did not significantly inhibit tumor growth (Fig. 5C) , whereas mice treated with AV22EL induced a strong delay in tumor growth in 100% of mice (Fig. 5C ). Adding 5-FU in combination with the CRAd did not significantly improve the tumor growthinhibitory effect observed with AV22EL alone (Fig. 5C ). We observed no evidence of toxicity or weight loss associated with the treatments that included the CRAd alone or combined with 5-FU (data not shown).
Liver metastases elimination follou'ing systemic AV22EL delivery. Eradication of hepatic metastases is a key factor for improved CRC prognosis (1). Therefore, we used an efficient model for metastases development in the liver by injecting nude mice in their portal vein with CRC cells. After we have confirmed that hepatic metastases developed, we assessed whether systemic administration of AV22EL might suppress growth of established tumor nodules.
Mice were treated with AV22EL, Ad-Pgal, or PBS at days 7, 10, and 14 after the initial cell injection. Seven days after the last viral administration, mice were sacrificed. Almost all the mice injected with Ad-Pgal or PBS developed multiple tumor nodules throughout the liver by day 21 after cell injection (Fig. 6A ). Mice treated with PBS or Ad-Pgal showed metastatic nodules that displayed areas with glandular-like arrangement of tumor cells (Fig. 6A, left) . Gross observation and histopatho logic analysis of autopsies confirmed that 10 of 11 mice injected with AV22EL were free of metastatic nodules (Fig. 6A,  right) , whereas 1 animal showed strongly reduced metastatic areas (data not shown). None of the mice injected with PBS or Ad-Pgal showed evidence of therapeutic benefit (Fig. 6A, right) . In addition, abundant expression of the adenovirus hexon protein was detected in tumor metastasis, but not in the normal liver, 72 hours after AV22EL administration (Fig. 6B) . Moreover, systemic administration of AV22EL led to E1A mRNA expression only in liver metastatic nodules, whereas other organs, such as spleen, kidney, intestine, lung, and nonmetastatic liver, exhibited no E1A expression (Fig. 6C, left) . Similarly, systemic administration of AV-Luc, where luciferase activity was driven by the A3 3 promoter, showed activity exclusively in liver metastatic nodules (Fig. 6C, right) .
To establish whether administration of AV22EL might affect liver function, we also assessed liver enzymes as a surrogate readout of liver toxicity. Growth of metastatic nodules in mice treated with PBS or control Ad-Pgal adenovirus decreased albumin levels while inducing an increase in aspartate aminotransferase and alkaline phosphatase levels (Fig. 6D) . Interestingly, albumin levels seemed normal in mice treated with AV22EL, whereas the differences in albumin levels remained statistically significant between the "no tumor" group compared with the Ad-Pgal or PBS groups of mice (Fig. 6D) . Aspartate aminotransferase levels also seemed normal in the AV22EL-treated group, whereas the Ad-Pgal group also exhibited diminished levels compared with the PBS-treated group (Fig. 6D) . Alkaline phosphatase differences were not statistically significant between the different groups, although alkaline phosphatase levels in the AV22EL group were similar to those observed in the no tumor group (Fig. 6D) . These data suggest that AV22EL not only was therapeutically efficient to inhibit metastatic growth but also was able to restore the normal function of the liver.
Discussion
Here, we show that a conditionally replicative oncolytic adenovirus based on the A33 promoter was able to inhibit the in vivo growth in nude mice of established colorectal carcinoma and eliminated established hepatic metastases. AV22EL was highly selective because it was completely ineffective on cells that did not express A3 3.
Most of the oncolytic viruses are developed based on promoters that can be active in more than a single cancer type to allow for a wider use without the therapeutic limitation of using the oncolytic virus in only one cancer type. This is the case for the CEA, COX-2, T-cell factor, and telomerase promoters that have been mentioned in Introduction. An additional CRAd based on a double heterologous promoter Ki67 and COX-2 showed significant oncolytic activity on s.c. established colorectal tumors, although its effectiveness on established hepatic metastases was not assessed (38) . More recently, a CRAd expressing El A driven by the nonspecific Rous sarcoma virus promoter and the proapoptotic protein tumor necrosis factor-related apoptosis-inducing ligand was effective in inducing the elimination of established metastases obtained from colon carcinoma cells (39 (46) . Recent data show that its administration through the hepatic artery to patients with metastatic CRC involving the liver exerted only minimal toxicity (47) . Because fresh human CRC samples exhibited high expression levels of coxsackie-adenoviral recep tor, the natural receptor of adenovirus type 5 (48) , it can be proposed that oncolytic viruses based on adenovirus type 5 with strong and selective lytic capacity, such as AV22EL, which is highly attenuated in hepatic cells, might represent an alternative to existing oncolytic viruses for systemic administration.
The human A33 antigen is a Mr 43,000 cell membrane glycoprotein that has become a target for antibody immuno therapy due to its restricted localization in colon cancer as well as in metastatic lesions of the same origin (24) . The humanized antibody (huA33) has led to the initiation of a phase I clinical trials with encouraging results (26) . The iodinated antibody has shown selective localization and deep penetration even in large necrotic tumors, suggesting that huA33 might become a therapeutic tool for cancer immunotherapy (24) . However, in two clinical studies, patients developed anti-huA33 anti bodies, limiting its potential therapeutic effect and the full manifestation of its potential clinical toxicities (49, suggesting that a less immunogenic compound might be necessary.
Here, we have shown the therapeutic efficacy of a novel CRAd whose replication is driven by the A3 3 promoter, providing an additional strategy that makes use of the tissue specific expression of this protein. Despite the fact that AV22EL exhibited lower replication capacity than WT adenovirus in vitro, it showed intratumor replicating capacity similar to www.aacrjournals.orgthat attained in breast cancer for a CRAd that targets the G, -S checkpoint (Ad-dl922-947) and higher than Ad-Onyx-O17 that targets p53 (36) . Thus, AV22EL was highly effective on primary tumors and hepatic metastasis of CRC with no cytocidal effect on normal colon derived cells, could be combined with current chemotherapeutic treatments, restored the normal hepatic function after the elimination of hepatic metastasis, and after systemic administration was strictly active in hepatic metasta ses, avoiding normal organs. Given the evidence of the mild adverse effects of oncolytic adenovirus therapeutics, we believe that AV22EL might become a useful tool for treatment of patients with CRC.
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